证券代码：600572 证券简称：康恩贝 公告编号：2024-042 浙江康恩贝制药股份有限公司 关于公司股东所持部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●浙江康恩贝制药股份有限公司（以下简称：本公司、公司）股东胡季强现持有本公司无限 售流通股 102,579,085 股，占本公司总股本 2,570,037,319 股的 3.99%；胡季强及其一致行动人 （康恩贝集团有限公司、浙江元中和生物产业发展有限公司）合计持有本公司股份 362,769,319 股，占本公司总股本的 14.11%。2024 年 6 月 25 日，胡季强将其持有的 64,000,000 股无限售流 通股质押给中信证券股份有限公司（其中 61,000,000 股为股份质押展期），并办理了股票质押式 回购交易。 ●截至公告披露日，胡季强及其一致行动人累计质押所持本公司股份数量 69,750,000 股， 占其合计持有本公司股份的 19.23%，占本公司总股份的 2.71%。 2024 年 6 月 26 日，公司接股东 ...

证券简称：康恩贝 证券代码：600572 编号：2024-040 浙江康恩贝制药股份有限公司 关于公司他达拉非片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称公司、本公司）收到国家药品监督管 理局（以下简称：国家药监局）核准签发的规格为 5mg、20mg 的他达拉非片《药品注册证 书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：他达拉非片 剂型：片剂 规格：5mg、20mg 注册分类：化学药品 4 类 证书编号：2024S00896、2024S00759 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 他达拉非片由美国礼来制药公司研制开发，分别于 2002 年 11 月、2003 年 11 月在欧 盟和美国获批，商品名为 Cialis®，并于 2004 年 12 月在国内获批上市。该药品主要用于 治疗男性勃起功能障碍（ED）。 本公司于 2022 年 6 ...

证券简称：康恩贝 证券代码：600572 编号：2024-041 浙江康恩贝制药股份有限公司 关于全资子公司盐酸文拉法辛缓释胶囊 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称：公司、本公司）全资子公司杭州康 恩贝制药有限公司（以下简称：杭州康恩贝）收到国家药品监督管理局（以下简称：国家 药监局）核准签发的规格为 75mg（按 C₁₇H₂₇NO₂计）的盐酸文拉法辛缓释胶囊《药品注册 证书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：盐酸文拉法辛缓释胶囊 剂型：胶囊剂 批准文号：国药准字 H20244035 证书编号：2024S01206 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 盐酸文拉法辛缓释胶囊由美国惠氏公司研制开发，于 1997 年首次在瑞士上市，同年 10 月在美国获批，并于 2000 年在国内获批上市。该药品用于治疗抑郁症（包括伴有焦虑 ...

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for future performance [49]. Core Insights - The company is focused on the traditional Chinese medicine (TCM) sector, with a clear strategy to enhance its core business in TCM while expanding its product offerings in chemical drugs and health consumer products [20][57]. - The company has seen significant growth in its key products, with the "Kang En Bei" brand's intestinal medicine series achieving nearly 1.3 billion in sales, and the "Zhi Xin Zai" musk heart drop continuing to gain traction in the market [5][26][58]. - The company is expected to benefit from potential adjustments to the national essential drug list, which may increase the proportion of TCM products [34][35]. Summary by Sections Company Strategy and Performance - The company has established a long-term incentive mechanism, including a stock option plan that aims to align employee interests with company performance [2]. - The company has a strong focus on brand and academic development, cultivating well-known TCM OTC products [4][20]. - The company has experienced a rebound in sales, with a projected revenue growth rate of 14% for its TCM business from 2024 to 2026 [47]. Product Performance - The "Kang En Bei" intestinal medicine series has maintained a leading position in the domestic market, with sales growth of 30% in 2023 [5]. - The "Jin Di" compound honeysuckle syrup has returned to a growth trajectory, with expectations for further sales increases [6]. - The "Tian Bao Ning" ginkgo leaf product has opened up hospital markets through successful bidding in multiple provinces [11]. Financial Projections - The company forecasts net profits of 760 million, 847 million, and 935 million for 2024, 2025, and 2026 respectively, with growth rates of 28.5%, 11.4%, and 10.3% [49][71]. - The company is currently undervalued, with a projected PE ratio of 17.6x for 2024, indicating potential for valuation recovery [49]. Market Position and Competitive Advantage - The company has a diversified product portfolio, focusing on TCM, chemical drugs, and health consumer products, which positions it well for future growth [20][47]. - The company has made strategic acquisitions to enhance its capabilities in the TCM sector, including a significant stake in a TCM university's herbal medicine company [29][73].

Investment Rating - The report gives an "Outperform" rating for the company, with a target price of 7.27 RMB based on a 25X PE for 2024 [42]. Core Viewpoints - The company has successfully reversed its previous difficulties and is now entering a stable growth phase, achieving a revenue of 6.733 billion RMB in 2023, a year-on-year increase of 12.20% [63]. - The company focuses on the traditional Chinese medicine (TCM) health sector, emphasizing resource integration and continuous optimization of its business structure [63]. - The company aims to enhance its brand strategy and product matrix, with plans to increase the sales scale of its key products [41]. Summary by Sections 1. Business Strategy and Performance - The company has gradually divested non-core businesses and is concentrating on the TCM health sector, which has led to improved operational efficiency and profitability [60][63]. - The company reported a net profit of 554 million RMB in 2023, reflecting a 14.60% year-on-year growth, indicating a recovery to historical performance levels [63][24]. 2. Product and Brand Development - The company has established a "one body, two wings" product strategy, focusing on a full range of TCM products while also developing specialty chemical drugs and health consumer products [14][41]. - In 2023, the company achieved sales of over 1 billion RMB for 17 product series, contributing to 68.6% of total revenue [41][14]. 3. Research and Development - The company has increased its R&D investment, with a R&D expense ratio of 4.43% in 2023, up nearly 1 percentage point from 2021 [5][7]. - The company is actively pursuing innovative drug development, with 200 ongoing projects, including 57 new projects initiated in 2023 [7][8]. 4. Financial Performance - The company’s revenue from TCM health products reached 4.544 billion RMB in 2023, a 16.13% increase from the previous year, accounting for 67.49% of total revenue [26][28]. - The company’s gross profit margin has stabilized, with a non-GAAP net profit margin of 8.32% in 2023, reflecting improved profitability [30][32]. 5. Market Position and Competitive Advantage - The company has strengthened its market position in the non-prescription drug sector, ranking among the top 10 non-prescription drug manufacturers in China [35][41]. - The company is leveraging digital marketing and e-commerce partnerships to expand its market reach and enhance brand visibility [33][41].

证券简称：康恩贝 证券代码：600572 编号：临 2024-039 浙江康恩贝制药股份有限公司 关于参加 2023 年报沪市主板大健康 集体业绩说明会情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司、康恩贝）于2024年6月4日 13:30-16:30通过上证路演中心视频直播和网络互动的方式参加了由上海证券交易所举 办的2023年报沪市主板大健康集体业绩说明会，公司董事、总裁罗国良先生，董事、 副总裁、财务总监谌明先生，副总裁、董事会秘书金祖成先生，独立董事吕久琴女士 出席本次业绩说明会。 公司管理层就公司2023年度和2024年第一季度的经营业绩、重点工作、发展规划 等具体情况与投资者进行了充分交流，在信息披露允许的范围内对主持人提问、现场 投资者提问以及网上投资者的实时提问进行了回答。具体内容详见附件《公司关于参 加2023年报沪市主板大健康集体业绩说明会纪要》。 关于公司参加2023年报沪市主板大健康集体业绩说明会的详细情况，可登录由上 海证券交易所上证路演中心（网 ...

证券代码：600572 证券简称：康恩贝 公告编号：2024-038 浙江康恩贝制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/23，由公司董事长胡季强先生提议 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过回购股份方案之日起 6 个月内 | | 预计回购金额 | 万元（人民币，下同） 20,000 万元—40,000 | | 回购用途 | 用于实施股权激励 | | 累计已回购股数 | 5,140.4645 万股 | | 累计已回购股数占总股本比例 | 2.00% | | 累计已回购金额 | 24,596.63 万元 | | 实际回购价格区间 | 4.08 元/股—5.00 元/股 | 一、回购股份的基本情况 浙江康恩贝制药股份有限公司(以下简称：公司)于 2024 年 1 月 22 日召开了十 届董事会第三十七次（临时）会议，审议通过《关于以集中竞价交易方式回购公 司股份的议案 ...

Investment Rating - The report assigns an "Outperform" rating to the company [17]. Core Viewpoints - The company focuses on the pharmaceutical health sector, primarily engaged in the research, manufacturing, and sales of medicines and health products, with a strategic emphasis on traditional Chinese medicine and health products [3][27]. - The company has undergone significant restructuring since the entry of state-owned capital, optimizing its business structure and focusing on the traditional Chinese medicine health industry [27][62]. - The company has achieved stable growth in its main business, with a reported revenue of 6.733 billion yuan in 2023, reflecting a year-on-year increase of 12.20% [27][88]. Summary by Relevant Sections Business Strategy - The company has adopted a "one body, two wings" product strategy, focusing on a full range of traditional Chinese medicine products while also developing specialty chemical drugs and health consumer products [21][66]. - The company has successfully cultivated multiple well-known brands, with 17 product series achieving over 100 million yuan in sales in 2023, contributing to 68.6% of total revenue [21][66]. Financial Performance - The company forecasts net profits of 747 million yuan, 837 million yuan, and 956 million yuan for 2024, 2025, and 2026, respectively, with corresponding EPS of 0.29 yuan, 0.33 yuan, and 0.37 yuan [22]. - The company reported a gross margin of 58.5% in 2023, with expectations for stability in gross margins as the business structure continues to optimize [23][67]. Research and Development - The company increased its R&D investment to 312 million yuan in 2023, accounting for 5.29% of manufacturing revenue, with a focus on innovative drug development and evidence-based medicine research [70]. - The company has a pipeline of 200 ongoing projects, with a significant portion dedicated to innovative and modified new drugs [70]. Market Position - The company ranks among the top 10 non-prescription drug manufacturers in China, with its "Kang En Bei" brand leading the market in gastrointestinal medications [79]. - The gastrointestinal medication market is projected to reach 63.32 billion yuan in 2024, with the company's products positioned to capture significant market share [79].

股票简称：康恩贝 股票代码：600572 公告编号：临 2024-037 号 浙江康恩贝制药股份有限公司 关于参加2023年报沪市主板大健康 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、 会议主题：2023年报沪市主板大健康集体业绩说明会 2、 会议召开时间：2024年6月4日（星期二）13:30-16:30 3、 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 4、 会议召开方式：上证路演中心视频和网络互动 5、投资者可于2024年5月28日(星期二)至6月3日(星期一)16:00前通过公司相关工作人员邮 箱wangyang@conbapharm.com进行提问。公司将在本次说明会上对投资者普遍关注的问题进行 回答。 （二） 会 议 召 开 地 点 ： 上 证 路 演 中 心 网 站 （ 网 址 ： https://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 三、参 ...

证券代码：600572 证券简称：康恩贝 公告编号：2024-036 浙江康恩贝制药股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.2 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/5/30 | － | 2024/5/31 | 2024/5/31 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 本次利润分配方案经浙江康恩贝制药股份有限公司（以下简称：公司、本公 司）2024 年 5 月 10 日的 2023 年年度股东大会审议通过。 二、 分配方案 （一）发放年度：2023 年年度 （二）分派对象： （三）差异化分红送转方案： 1、差异化分红方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称：中国结算上海分公司）登记在册的 ...